Home The Word Brain	My Amedeo FAQ Privacy About	Flying Publisher
	OLIENA Language recovery after stroke App | Video | PDF (278 pp) | Web

Dyslipidemia

Free Subscription Articles published in JAMA Retrieve available abstracts of 14 articles: HTML format Text format

Single Articles

October 2018
1. KING WC, Hinerman AS, Belle SH, Wahed AS, et al
   Comparison of the Performance of Common Measures of Weight Regain After Bariatric Surgery for Association With Clinical Outcomes.
   JAMA. 2018;320:1560-1569.
   PubMed     Text format     Abstract available
   
   
   January 2018
2. SALMINEN P, Helmio M, Ovaska J, Juuti A, et al
   Effect of Laparoscopic Sleeve Gastrectomy vs Laparoscopic Roux-en-Y Gastric Bypass on Weight Loss at 5 Years Among Patients With Morbid Obesity: The SLEEVEPASS Randomized Clinical Trial.
   JAMA. 2018;319:241-254.
   PubMed     Text format     Abstract available
   
   
   December 2017
3. GREENLAND P
   Cardiovascular Guideline Skepticism vs Lifestyle Realism?
   JAMA. 2017 Dec 14. pii: 2666625. doi: 10.1001/jama.2017.19675.
   PubMed     Text format    
   
   
   August 2017
4. FERENCE BA, Kastelein JJP, Ginsberg HN, Chapman MJ, et al
   Association of Genetic Variants Related to CETP Inhibitors and Statins With Lipoprotein Levels and Cardiovascular Risk.
   JAMA. 2017 Aug 28. doi: 10.1001/jama.2017.11467.
   PubMed     Text format     Abstract available
   
   
   
5. KAZI DS, Penko J, Coxson PG, Moran AE, et al
   Updated Cost-effectiveness Analysis of PCSK9 Inhibitors Based on the Results of the FOURIER Trial.
   JAMA. 2017;318:748-750.
   PubMed     Text format    
   
   
   
6. KRUMHOLZ HM
   Treatment of Cholesterol in 2017.
   JAMA. 2017;318:417-418.
   PubMed     Text format    
   
   
   July 2017
7. KNOWLES JW, Rader DJ, Khoury MJ
   Cascade Screening for Familial Hypercholesterolemia and the Use of Genetic Testing.
   JAMA. 2017;318:381-382.
   PubMed     Text format    
   
   
   
8. IOANNIDIS JPA
   Inconsistent Guideline Recommendations for Cardiovascular Prevention and the Debate About Zeroing in on and Zeroing LDL-C Levels With PCSK9 Inhibitors.
   JAMA. 2017 Jul 24. doi: 10.1001/jama.2017.6765.
   PubMed     Text format    
   
   
   
9. GROSSMAN DC, Bibbins-Domingo K, Curry SJ, Barry MJ, et al
   Behavioral Counseling to Promote a Healthful Diet and Physical Activity for Cardiovascular Disease Prevention in Adults Without Cardiovascular Risk Factors: US Preventive Services Task Force Recommendation Statement.
   JAMA. 2017;318:167-174.
   PubMed     Text format     Abstract available
   
   
   
10. PATNODE CD, Evans CV, Senger CA, Redmond N, et al
    Behavioral Counseling to Promote a Healthful Diet and Physical Activity for Cardiovascular Disease Prevention in Adults Without Known Cardiovascular Disease Risk Factors: Updated Evidence Report and Systematic Review for the US Preventive Services Tas
    JAMA. 2017;318:175-193.
    PubMed     Text format     Abstract available
    
    
    April 2017
11. SCHWARTZ MLB, Williams MS, Murray MF
    Adding Protective Genetic Variants to Clinical Reporting of Genomic Screening Results: Restoring Balance.
    JAMA. 2017;317:1527-1528.
    PubMed     Text format    
    
    
    
12. GOTTESMAN RF, Schneider AL, Zhou Y, Coresh J, et al
    Association Between Midlife Vascular Risk Factors and Estimated Brain Amyloid Deposition.
    JAMA. 2017;317:1443-1450.
    PubMed     Text format     Abstract available
    
    
    November 2016
13. BIBBINS-DOMINGO K, Grossman DC, Curry SJ, Davidson KW, et al
    Statin Use for the Primary Prevention of Cardiovascular Disease in Adults: US Preventive Services Task Force Recommendation Statement.
    JAMA. 2016;316:1997-2007.
    PubMed     Text format     Abstract available
    
    
    August 2016
14. KAZI DS, Moran AE, Coxson PG, Penko J, et al
    Cost-effectiveness of PCSK9 Inhibitor Therapy in Patients With Heterozygous Familial Hypercholesterolemia or Atherosclerotic Cardiovascular Disease.
    JAMA. 2016;316:743-53.
    PubMed     Text format     Abstract available
    
    

Thank you for your interest in scientific medicine.

AMEDEO Dyslipidemia is free of charge. This policy is made possible thanks to a media sponsorship by Boehringer Ingelheim. Design: